Roivant Sciences Ltd. $ROIV Stock Position Decreased by Penn Davis Mcfarland Inc.

Penn Davis Mcfarland Inc. cut its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 14.3% in the first quarter, HoldingsChannel reports. The fund owned 1,592,623 shares of the company’s stock after selling 265,666 shares during the period. Roivant Sciences makes up approximately 4.3% of Penn Davis Mcfarland Inc.’s holdings, making the stock its 7th largest holding. Penn Davis Mcfarland Inc.’s holdings in Roivant Sciences were worth $44,116,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UBS Group AG lifted its holdings in Roivant Sciences by 570.0% during the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after purchasing an additional 15,645,836 shares in the last quarter. Morgan Stanley increased its stake in shares of Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after purchasing an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after purchasing an additional 8,621,567 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Roivant Sciences by 11,507.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after purchasing an additional 6,877,348 shares during the period. Finally, Norges Bank bought a new stake in shares of Roivant Sciences during the 4th quarter valued at $112,750,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Stock Performance

ROIV stock opened at $34.02 on Friday. The company’s fifty day moving average price is $29.57 and its 200-day moving average price is $26.72. Roivant Sciences Ltd. has a one year low of $10.70 and a one year high of $34.68. The company has a market capitalization of $24.47 billion, a PE ratio of -56.70 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.57. The company had revenue of $2.52 million during the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same period last year, the company posted ($0.29) earnings per share. On average, research analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Citigroup raised their price target on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Leerink Partners set a $42.00 price objective on Roivant Sciences in a research note on Thursday, May 21st. Finally, TD Cowen upped their price objective on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Insider Buying and Selling at Roivant Sciences

In other news, CAO Jennifer Humes sold 13,538 shares of the firm’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total transaction of $384,073.06. Following the completion of the transaction, the chief accounting officer owned 84,191 shares in the company, valued at $2,388,498.67. This trade represents a 13.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Matthew Gline sold 289,774 shares of Roivant Sciences stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the sale, the chief executive officer directly owned 16,736,116 shares in the company, valued at $488,025,142.56. This trade represents a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 703,312 shares of company stock valued at $20,805,883 in the last 90 days. Insiders own 10.80% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.